Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 232817, 6 pages
http://dx.doi.org/10.1155/2014/232817
Review Article

Application of MicroRNA in Diagnosis and Treatment of Ovarian Cancer

Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan

Received 10 December 2013; Revised 5 March 2014; Accepted 5 March 2014; Published 15 April 2014

Academic Editor: Yong-Sang Song

Copyright © 2014 Kouji Banno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Yahata, C. Banzai, K. Tanaka, and Niigata Gynecological Cancer Registry, “Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007,” Journal of Obstetrics and Gynaecology Research, vol. 38, pp. 645–650, 2012. View at Google Scholar
  3. E. Weiderpas, S. Sandin, M. Inoue et al., “Risk factors for epithelial ovarian cancer in Japan: results from the Japan Public Health Center-based Prospective Study cohort,” International Journal of Oncology, vol. 40, no. 1, pp. 21–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Heintz, F. Odicino, P. Maisonneuve et al., “Carcinoma of the Ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer,” International Journal of Gynecology and Obstetrics, vol. 95, supplement 1, pp. S161–S192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Shimasaki, R. K. Moore, G. F. Erickson, and F. Otsuka, “The role of bone morphogenetic proteins in ovarian function,” Reproduction, vol. 61, pp. 323–337, 2003. View at Google Scholar · View at Scopus
  7. T. Minegishi, T. Kameda, T. Hirakawa, K. Abe, M. Tano, and Y. Ibuki, “Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms,” Clinical Cancer Research, vol. 6, no. 7, pp. 2764–2770, 2000. View at Google Scholar · View at Scopus
  8. Y. Mase, O. Ishibashi, T. Ishikawa et al., “MiR-21 is enriched in the RNA-induced silencing complex and targets COL4A1 in human granulosa cell lines,” Reproductive Sciences, vol. 19, pp. 1030–1040, 2012. View at Google Scholar
  9. E. P. Murchison, P. Stein, Z. Xuan et al., “Critical roles for Dicer in the female germline,” Genes and Development, vol. 21, no. 6, pp. 682–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. V. Iorio, R. Visone, G. Di Leva et al., “MicroRNA signatures in human ovarian cancer,” Cancer Research, vol. 67, no. 18, pp. 8699–8707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. P. Bracken, P. A. Gregory, N. Kolesnikoff et al., “A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition,” Cancer Research, vol. 68, no. 19, pp. 7846–7854, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. W. M. Merritt, Y. G. Lin, L. Y. Han et al., “Dicer, Drosha, and outcomes in patients with ovarian cancer,” The New England Journal of Medicine, vol. 359, no. 25, pp. 2641–2650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Hong, Z. Yang, J. Ma, and D. Fan, “Function of miRNA in controlling drug resistance of human cancers,” Current Drug Targets, vol. 14, pp. 1118–1127, 2013. View at Google Scholar
  14. N. Yang, S. Kaur, S. Volinia et al., “MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer,” Cancer Research, vol. 10, pp. 2687–2693, 2004. View at Google Scholar
  15. T. Mitamura, H. Watari, L. Wang et al., “Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET,” Oncogenesis, vol. 2, article e40, 2013. View at Google Scholar
  16. R. I. Aqeilan, G. A. Calin, and C. M. Croce, “MiR-15a and miR-16-1 in cancer: discovery, function and future perspectives,” Cell Death and Differentiation, vol. 17, no. 2, pp. 215–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Leskelä, L. J. Leandro-García, M. Mendiola et al., “The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients,” Endocrine-Related Cancer, vol. 18, no. 1, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Boyerinas, S.-M. Park, A. E. Murmann et al., “Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1,” International Journal of Cancer, vol. 130, no. 8, pp. 1787–1797, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Lu, P. Schwartz, L. Scarampi et al., “MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management,” Gynecologic Oncology, vol. 122, no. 2, pp. 366–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. K. Nagaraja, C. J. Creighton, Z. Yu et al., “A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer,” Molecular Endocrinology, vol. 24, no. 2, pp. 447–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D.-X. Peng, M. Luo, L.-W. Qiu, Y.-L. He, and X.-F. Wang, “Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer,” Oncology Reports, vol. 27, no. 4, pp. 1238–1244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Fu, J. Tian, L. Zhang, Y. Chen, and Q. Hao, “Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells,” FEBS Letters, vol. 586, no. 9, pp. 1279–1286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. T. M. van Jaarsveld, J. Helleman, E. M. J. J. Berns, and E. A. C. Wiemer, “MicroRNAs in ovarian cancer biology and therapy resistance,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1282–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Laios, S. O'Toole, R. Flavin et al., “Potential role of miR-9 and miR-223 in recurrent ovarian cancer,” Molecular Cancer, vol. 7, article 35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. J. Nam, H. Yoon, S. W. Kim et al., “MicroRNA expression profiles in serous ovarian carcinoma,” Clinical Cancer Research, vol. 14, no. 9, pp. 2690–2695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Zhang, S. Volinia, T. Bonome et al., “Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 19, pp. 7004–7009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Eitan, M. Kushnir, G. Lithwick-Yanai et al., “Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients,” Gynecologic Oncology, vol. 114, no. 2, pp. 253–259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. F. Gallagher, R. J. Flavin, S. A. Elbaruni et al., “Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients,” Journal of Ovarian Research, vol. 2, no. 1, article 19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C.-H. Lee, S. Subramanian, A. H. Beck et al., “MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary,” PLoS ONE, vol. 4, no. 10, Article ID e7314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. K. Wyman, R. K. Parkin, P. S. Mitchell et al., “Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries,” PLoS ONE, vol. 4, no. 4, Article ID e5311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Toloubeydokhti, O. Bukulmez, and N. Chegini, “Potential regulatory functions of MicroRNAs in the ovary,” Seminars in Reproductive Medicine, vol. 26, no. 6, pp. 469–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. J. Creighton, M. D. Fountain, Z. Yu et al., “Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers,” Cancer Research, vol. 70, no. 5, pp. 1906–1915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. M. Voorhoeve, C. le Sage, M. Schrier et al., “A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors,” Cell, vol. 124, no. 6, pp. 1169–1181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Yukihiro, Y. Nozomu, Y. Noriko, O. Kazunori, and O. Aikou, “MicroRNA-21 overexpression through the 17q21-24 amplication regulates PTEN tumor suppressor gene expression in ovarian clear cell carcinoma,” Acta Obstetrica Et Gynaecologya Japonica, vol. 65, artile 860, 2013. View at Google Scholar
  35. R. Garzon, G. Marcucci, and C. M. Croce, “Targeting microRNAs in cancer: rationale, strategies and challenges,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 775–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Lu, J. Xiao, H. Lin et al., “A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference,” Nucleic Acids Research, vol. 37, no. 3, article e24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Dai, Y. Zhang, X. Zhu, N. Shan, and Y. Chen, “Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation,” Targeted Oncology, vol. 7, pp. 217–225, 2012. View at Google Scholar
  38. C. Ohyagi-Hara, K. Sawada, S. Kamiura et al., “miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression,” The American Journal of Pathology, vol. 182, pp. 1876–1889, 2013. View at Google Scholar
  39. D. M. Cittelly, I. Dimitrova, E. N. Howe et al., “Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel,” Molecular Cancer Therapeutics, vol. 11, pp. 2556–2565, 2012. View at Google Scholar
  40. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Kosaka, H. Iguchi, Y. Yoshioka, F. Takeshita, Y. Matsuki, and T. Ochiya, “Secretory mechanisms and intercellular transfer of microRNAs in living cells,” Journal of Biological Chemistry, vol. 285, no. 23, pp. 17442–17452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Kosaka, H. Izumi, K. Sekine, and T. Ochiya, “MicroRNA as a new immune-regulatory agent in breast milk,” Silence, vol. 1, no. 1, article 7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Gnyszka, Z. Jastrzebski, and S. Flis, “DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer,” Anticancer Research, vol. 33, pp. 2989–2996, 2013. View at Google Scholar
  44. A. R. Walker, R. B. Klisovic, R. Garzon et al., “Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia,” Leukemia Lymphoma. In press.
  45. A. F. Andrade, K. S. Borges, A. M. Castro-Gamero et al., “Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells,” Anticancer Drugs, vol. 25, pp. 72–81, 2014. View at Google Scholar
  46. F. Fang, C. Balch, J. Schilder et al., “A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer,” Cancer, vol. 116, no. 17, pp. 4043–4053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Sessa, W. Ten Bokkel Huinink, G. Stoter, J. Renards, and F. Cavalli, “Phase II study of 5-Aza-′-deoxycytidine in advanced ovarian carcinoma,” European Journal of Cancer, vol. 26, no. 2, pp. 137–138, 1990. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Matei, F. Fang, C. Shen et al., “Epigenetic resensitization to platinum in ovarian cancer,” Cancer Research, vol. 72, no. 9, pp. 2197–2205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Liu, Z. Xiao, S. K. Wong et al., “Lung cancer tumorigenicity and drug resistance are maintained through ALDHhiCD44hi tumor initiating cells,” Oncotarget, vol. 4, pp. 1686–1699, 2013. View at Google Scholar
  50. B. Li, X. L. Cheng, Y. P. Yang, and Z. Q. Li, “GRP78 mediates radiation resistance of a stem cell-like subpopulation within the MCF-7 breast cancer cell line,” Oncology Reports, vol. 30, pp. 2119–2126, 2013. View at Google Scholar
  51. K. Yasuda, T. Torigoe, R. Morita et al., “Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population,” PLoS ONE, vol. 8, Article ID e68187, 2013. View at Google Scholar